Economic Costs and Disability-Adjusted Life Years in Polio Eradication: A Long-Run Global Perspective

  • M. M. Khan


This paper estimates the costs and effectiveness of polio immunization and eradication activities from long-term global perspective. The effectiveness of immunization has been expressed in terms of Disability Adjusted Life Years ( DALYs) averted over the years 1970–2050 and the aggregate effectiveness was calculated using 2007 present values. The projected annual numbers of polio cases without vaccination were obtained from polio case-loads in pre-vaccination era in the USA and in Europe. Costs of routine polio immunization and eradication activities were also expressed in terms of 2007 dollars. The results indicate that polio immunization will prevent more than 42 million cases of polio, four million paralysis and 855 thousand deaths over the years 1970–2050. In terms of 2007 dollars, the aggregate global cost of polio immunization over 1970–2050 will exceed $123 billion. Despite the high cost of the program, direct medical care cost savings associated with polio prevention are so high that the program becomes cost-saving at the global level. Excepting for few low income countries in Africa and South-east Asia, routine polio immunization remains a  highly cost-effective intervention for all countries of the world. Even for poorer countries, polio immunization and eradication activities remain cost-effective. However, very poor countries will require continued financial assistance to help achieve the full economic benefit of polio immunization and eradication.


Routine Immunization Gross National Income Oral Polio Vaccine Disability Adjust Life Polio Eradication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


acute flaccid paralysis


Africa region of WHO


region of the Americas


disability adjusted life years


eastern mediterranean region


expanded program for immunization


European region


 gross national income


International Classification of Disease version 10


inactivated polio vaccine


National Immunization Days


oral polio vaccine


south-east Asia region


western pacific region


years lost due to disability for the incident cases of health conditions


years of life lost due to premature death


  1. Bart KJ, Foulds J, Patriarca P. (1996). Bull World Health Organ. 74(1): 35–45.PubMedGoogle Scholar
  2. Brenzel L, Claquin P. (1994). Soc Sci Med. 39(4): 527–536.PubMedCrossRefGoogle Scholar
  3. CDC(1998). JAMA. 279(2): 103–104.CrossRefGoogle Scholar
  4. Cockburn WC, Drozdov SG. (1970). Bull World Health Organ. 42: 405–417.PubMedGoogle Scholar
  5. Fairbrother G, DuMont KA. (1995). Am J Public Health. 85(12): 1662–1665.PubMedCrossRefGoogle Scholar
  6. Jian Z, Jing-jin Y, Rong-zhen Z, et al. (1998). Int J Health Plan Manage. 13: 5–25.CrossRefGoogle Scholar
  7. Kaddar M, Levin A, Dougherty L, Maceira D. (2000). Costs and Financing of Immunization Programs: Findings of Four Case Studies. Partnerships for Health Reform Project, Abt Associates Inc., May.Google Scholar
  8. Kaddar M, Mookherji S, DeRoeck D, Antona D. (1999). Case Study on the Costs and Financing of Immunization Services in Morocco. Special Initiatives Report number 18, Partnerships for Health Reform Project, Abt Associates Inc., September.Google Scholar
  9. Khan M, Yoder R. (1998). Expanded Program on Immunization in Bangladesh: Cost, Cost-effectiveness, and Financing Estimates. Technical Report number 24, Parnerships for Health Reform Project, Abt Associates Inc., September.Google Scholar
  10. Levin A, Ram S, Afsar A, et al. (2000a). The Cost-effectiveness of Mixes of Operational Approaches to Polio Eradication: Findings of Two Case Studies. Special Initiatives Report Number 32, Partnerships for Health Reform Project, Abt Associates Inc., October.Google Scholar
  11. Levin A, Ram S, Kaddar M. (2000b). The Impact of the Polio Eradication Campaign on the Financing of Routine EPI: Finding of three Case Studies. Special Initiative Report number 27, Partnerships for Health Reform Project, Abt Associates Inc., March.Google Scholar
  12. Liu X, Levin A, Makinen M, Day J. (2002). OPV vs IPV: Past and Future Choice of Vaccine in the Global Polio Eradication Program. Partnerships for Health Reformplus Project, February.Google Scholar
  13. Mathers C, Loncar D. (2006). Updated projections of global mortality and burden of disease, 2002–2030: Data sources, methods and results. Evidence and information for policy working paper, World Health Organization, Geneva, November.Google Scholar
  14. Murray CJL, Lopez AD, (eds.). (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambridge.Google Scholar
  15. Musgrove P. (1989). Is Polio Eradication in the Americas Economically Justified? in Health Economics: Latin American Perspectives, Pan American Health Organization, Scientific Publication no. 517.Google Scholar
  16. World Bank. (2006). World Development Report 2007. Washington DC.Google Scholar
  17. World Health Organization. (2000). Global Polio Eradication Initiative: Strategic Plan 2001–2005. Geneva.Google Scholar
  18. World Health Organization. (2002). Endgame issues for the global polio eradication initiative. Technical Consultative Group to Global Eradication of Polio, Clinical Infectious Diseases. 34: 1 January.Google Scholar
  19. World Health Organization. (2006). Global Program on Evidence for Health Policy (GPE), “Global burden of Poliomyelitis in the year 2000”, Global Burden of Disease 2000 Notes, Draft 15-08-06.Google Scholar
  20. World Health Organization. (2008). Conclusions and Recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 27–28 November 2007. Weekly Epidemiological Record. Year 83, number 3, 18 January, pp. 25–35.Google Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • M. M. Khan

There are no affiliations available

Personalised recommendations